John Cerio
Human Resources Officer at ORCHARD THERAPEUTICS PLC
Network origin in John Cerio first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 12 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to John Cerio via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| ESPERION THERAPEUTICS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
| KERYX BIOPHARMACEUTICALS | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal | |
| PTC THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Notre Dame | College/University | Undergraduate Degree | |
| MOLMED S.P.A. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| AGIOS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Public Communications Contact | |
| KYOWA KIRIN CO. LTD. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Orchard Therapeutics North America
 Orchard Therapeutics North America BiotechnologyHealth Technology Part of Orchard Therapeutics Plc, Orchard Therapeutics North America provides biotechnology research services. The company is based in Boston, MA. The CEO of the company is Bobby Gaspar. | Biotechnology | Director/Board Member Chief Executive Officer | |
Kyowa Kirin International Plc
 Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Biotechnology | President Founder | |
| San Raffaele-Telethon Institute for Gene Therapy | Director/Board Member | ||
| European Molecular Biology Organization | Corporate Officer/Principal | ||
American Society of Gene & Cell Therapy
 American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services The American Society of Gene & Cell Therapy is a medical and professional organization that represents researchers and scientists devoted to the discovery of gene and cell therapies. The American company was founded by Mark A. Kay. | Miscellaneous Commercial Services | Director/Board Member | |
Smart Immune SAS
 Smart Immune SAS BiotechnologyHealth Technology Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| UCL Institute of Child Health | Corporate Officer/Principal | ||
| Centre For Research In Rare Diseases In Children | Director/Board Member | ||
| King's College London | College/University | Graduate Degree | |
| University College London | College/University | Doctorate Degree | |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Medical/Nursing Services | Director/Board Member | |
| The Leonard N Stern School of Business | College/University | Masters Business Admin | |
| University of Pavia | College/University | Doctorate Degree | |
| CANDEL THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| Stanford University School of Medicine | College/University | Doctorate Degree | |
| Università degli Studi di Modena e Reggio Emilia | College/University | Corporate Officer/Principal | |
Genethon
 Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| AUDENTES THERAPEUTICS, INC. | Biotechnology | Corporate Officer/Principal | |
| SPERO THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| University of Michigan | College/University | Undergraduate Degree | |
Massachusetts Biotechnology Council
 Massachusetts Biotechnology Council Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell. | Miscellaneous Commercial Services | Director/Board Member | |
| AMAG PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
| LARIMAR THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| Università degli Studi di Roma Tor Vergata | College/University | Undergraduate Degree | |
Vifor Pharma Management AG
 Vifor Pharma Management AG Pharmaceuticals: MajorHealth Technology Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Bristol | College/University | Doctorate Degree | |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| MEREO BIOPHARMA GROUP PLC | Biotechnology | Director/Board Member | |
| University of Illinois | College/University | Masters Business Admin |
Statistics
International
| United States | 25 |
| United Kingdom | 9 |
| Italy | 6 |
| France | 3 |
| Switzerland | 3 |
Sectoral
| Health Technology | 23 |
| Consumer Services | 12 |
| Commercial Services | 5 |
| Technology Services | 2 |
| Health Services | 2 |
Operational
| Corporate Officer/Principal | 17 |
| Director/Board Member | 17 |
| Chief Tech/Sci/R&D Officer | 8 |
| Director of Finance/CFO | 6 |
| Chief Executive Officer | 6 |
Most connected contacts
| Insiders | |
|---|---|
| Frank Thomas | 14 |
| Fulvio Mavilio | 10 |
| Abdul Mullick | 9 |
| Bobby Gaspar | 8 |
| Yasuo Fujii | 4 |
| Braden Parker | 4 |
| Nicoletta Loggia | 3 |
| Leslie Meltzer | 3 |
| Renee T. Leck | 2 |
| Takeyoshi Yamashita | 2 |
| Benjamin Navon | 1 |
| Christopher York | 1 |
- Stock Market
- Insiders
- John Cerio
- Company connections
